Health
Goldman gave clients a list of stocks that may surge if a coronavirus vaccine is approved – CNBC
With several Covid-19 vaccines in Phase 3 trials, Goldman Sachs is preparing its clients for a rebound in certain stocks.
(This story is only for CNBC Pro subscribers)
With several Covid-19 vaccines in Phase 3 trials and preliminary data due as soon as later this month, Goldman Sachs is preparing its clients for a rebound in certain stocks and recommending tweaks to client portfolios.
It grouped a list of several U.S. equities into four buckets.
The first bucket includes stocks that have sold off in 2020 but should bounce back as people “‘return to normal.'” The second bucket is comprised of equities that appear…
-
Noosa News13 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General12 hours agoSingapore’s world-first sustainable flights tax will see some Australians pay more to travel
-
Noosa News13 hours agoBoy charged over E-Bike crash
-
General11 hours agoCrowe toasts talkback titan for platforming ‘voiceless’